Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05597020 · ClinicalTrials.gov registry record · Phase 4

A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia

A Phase 4 study of Nocturia and Insomnia Disorder, sponsored by Idorsia Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
60
Enrollment target
16
Study locations

NCT05597020 is a Phase 4 study of Nocturia and Insomnia Disorder that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 60 participants, below the 310-participant average among 9 other Nocturia trials with a reported enrollment target (81% lower). The trial reports 16 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05597020, a Phase 4 study of Nocturia and Insomnia Disorder, has completed, sponsored by Idorsia Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
60 participants
Enrollment target
16
Study locations

Study Summary

A study to find out if daridorexant is safe and efficacious in patients with insomnia and comorbid nocturia

Conditions Studied

Nocturia Insomnia Disorder

Interventions

  • DRUG Placebo
  • DRUG Daridorexant

Study Locations (16)

Other

  • Praxisklinik am Franziskushospital - Urologisches Zentrum Euregio - Aachen
  • ASR Advanced Sleep Research GmBH - Berlin
  • SOMNIBENE Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH - Schwerin
  • Complejo Hospitalario Universitario A Coruña - A Coruña
  • Hospital del Mar - Barcelona
  • UROCLINICA Barcelona - Barcelona
  • Hospital Universitario Puerta del Mar (HUPM) - Cadiz
  • Hospital Universitario Fundación Jiménez Díaz - Madrid
  • Hospital Universitario La Paz - Madrid
  • Hospital Universitario Central de Asturias - Oviedo
  • Hospitalario Universitario de Canarias - San Cristóbal de La Laguna

Florida

  • Quantum Clinical Trials - Miami Beach
  • Clinical Research Center of Florida - Pompano Beach
  • Encore Medical Research of Weston - Weston

Louisiana

  • Ochsner LSU Health Shreveport-Regional Urology - Shreveport

North Carolina

  • Accellacare Research of Cary - Cary

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2023-02-16
Est. Completion 2024-04-18
Phase Phase 4

Sponsor

Idorsia Pharmaceuticals

34 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05597020

The ClinicalTrials.gov registry entry for NCT05597020 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 9 other Nocturia trials with a reported enrollment target (81% lower). The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Nocturia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05597020 reports 16 study locations spanning 4 distinct geographic areas - top geographies include Other, Florida, Louisiana.

Frequently Asked Questions

What is clinical trial NCT05597020 about?

NCT05597020 is a clinical study titled "A Study to Find Out if Daridorexant is Safe and Efficacious in Patients With Insomnia and Comorbid Nocturia". A study to find out if daridorexant is safe and efficacious in patients with insomnia and comorbid nocturia

What is the current status of trial NCT05597020?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2023-02-16. Estimated completion is 2024-04-18.

What conditions does trial NCT05597020 study?

This clinical trial studies the following conditions: Nocturia, Insomnia Disorder.

What interventions are being tested in trial NCT05597020?

The interventions under investigation include: Placebo (DRUG), Daridorexant (DRUG).

Who is sponsoring clinical trial NCT05597020?

This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05597020 being conducted?

This trial has 16 study locations across Florida, Louisiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Nocturia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Nocturia

All registered trials for this condition

Insomnia Disorder

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.